Ziv Gan-Or1, Idan Amshalom2, Laura L Kilarski2, Anat Bar-Shira2, Mali Gana-Weisz2, Anat Mirelman2, Karen Marder2, Susan Bressman2, Nir Giladi2, Avi Orr-Urtreger1. 1. From The Genetic Institute (Z.G.-O., I.A., A.B.-S., M.G.-W., A.O.-R.) and Movement Disorders Unit, Parkinson Center, and Department of Neurology (A.M., N.G.), Tel Aviv Sourasky Medical Center; The Sackler Faculty of Medicine (N.G., A.O.-U.), Tel Aviv University, Israel; Stroke and Dementia Research Centre (L.L.K.), St. George's, University of London, UK; Columbia University (K.M.), Columbia Presbyterian Medical Center, New York; and Beth Israel Medical Center (S.B.), New York, NY. Z.G.-O. is currently affiliated with the Department of Human Genetics and Montreal Neurological Institute, McGill University, Montreal, Canada. aviorr@tasmc.health.gov.il ziv.gan-or@mail.mcgill.ca. 2. From The Genetic Institute (Z.G.-O., I.A., A.B.-S., M.G.-W., A.O.-R.) and Movement Disorders Unit, Parkinson Center, and Department of Neurology (A.M., N.G.), Tel Aviv Sourasky Medical Center; The Sackler Faculty of Medicine (N.G., A.O.-U.), Tel Aviv University, Israel; Stroke and Dementia Research Centre (L.L.K.), St. George's, University of London, UK; Columbia University (K.M.), Columbia Presbyterian Medical Center, New York; and Beth Israel Medical Center (S.B.), New York, NY. Z.G.-O. is currently affiliated with the Department of Human Genetics and Montreal Neurological Institute, McGill University, Montreal, Canada.
Abstract
OBJECTIVE: To better define the genotype-phenotype correlations between the type of GBA (glucosidase, beta, acid) mutation, severe or mild, and the risk and age at onset (AAO), and potential mechanism of Parkinson disease (PD). METHODS: We analyzed 1,000 patients of Ashkenazi-Jewish descent with PD for 7 founder GBA mutations, and conducted a meta-analysis of risk and AAO according to GBA genotype (severe or mild mutation). The meta-analysis included 11,453 patients with PD and 14,565 controls from worldwide populations. The statistical analysis was done with and without continuity correction (constant or empirical), considering biases that could potentially affect the results. RESULTS: Among Ashkenazi-Jewish patients with PD, the odds ratios for PD were 2.2 and 10.3 for mild and severe GBA mutation carriers, respectively. The observed frequency of severe GBA mutation carriers among patients with PD was more than 4-fold than expected (4.4% vs 0.9%, respectively, p < 0.0001, Fisher exact test). In the different models of the meta-analysis, the odds ratios for PD ranged between 2.84 and 4.94 for mild GBA mutation carriers and 9.92 and 21.29 for severe GBA mutation carriers (p < 1 × 10(-6) for all analyses). Pooled analysis demonstrated AAO of 53.1 (±11.2) and 58.1 (±10.6) years for severe and mild GBA mutation carriers, respectively (p = 4.3 × 10(-5)). CONCLUSIONS: These data demonstrate that mild and severe heterozygous GBA mutations differentially affect the risk and the AAO of PD. Our results have important implications for genetic counseling and clinical follow-up.
OBJECTIVE: To better define the genotype-phenotype correlations between the type of GBA (glucosidase, beta, acid) mutation, severe or mild, and the risk and age at onset (AAO), and potential mechanism of Parkinson disease (PD). METHODS: We analyzed 1,000 patients of Ashkenazi-Jewish descent with PD for 7 founder GBA mutations, and conducted a meta-analysis of risk and AAO according to GBA genotype (severe or mild mutation). The meta-analysis included 11,453 patients with PD and 14,565 controls from worldwide populations. The statistical analysis was done with and without continuity correction (constant or empirical), considering biases that could potentially affect the results. RESULTS: Among Ashkenazi-Jewish patients with PD, the odds ratios for PD were 2.2 and 10.3 for mild and severe GBA mutation carriers, respectively. The observed frequency of severe GBA mutation carriers among patients with PD was more than 4-fold than expected (4.4% vs 0.9%, respectively, p < 0.0001, Fisher exact test). In the different models of the meta-analysis, the odds ratios for PD ranged between 2.84 and 4.94 for mild GBA mutation carriers and 9.92 and 21.29 for severe GBA mutation carriers (p < 1 × 10(-6) for all analyses). Pooled analysis demonstrated AAO of 53.1 (±11.2) and 58.1 (±10.6) years for severe and mild GBA mutation carriers, respectively (p = 4.3 × 10(-5)). CONCLUSIONS: These data demonstrate that mild and severe heterozygous GBA mutations differentially affect the risk and the AAO of PD. Our results have important implications for genetic counseling and clinical follow-up.
Authors: S Lesage; C Condroyer; N Hecham; M Anheim; S Belarbi; E Lohman; F Viallet; P Pollak; M Abada; A Dürr; M Tazir; A Brice Journal: Neurology Date: 2011-01-18 Impact factor: 9.910
Authors: Anne Noreau; Jean-Baptiste Rivière; Sabrina Diab; Patrick A Dion; Michel Panisset; Valérie Soland; Nicolas Jodoin; Mélanie Langlois; Sylvain Chouinard; Nicolas Dupré; Guy A Rouleau Journal: Can J Neurol Sci Date: 2011-09 Impact factor: 2.104
Authors: M de L González-Del Rincón; N Monroy Jaramillo; A I Suárez Martínez; P Yescas Gómez; M C Boll Woehrlen; M López López; M E Alonso Vilatela Journal: Clin Genet Date: 2013-03-01 Impact factor: 4.438
Authors: L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder Journal: Neurology Date: 2007-09-18 Impact factor: 9.910
Authors: Reena V Kartha; James Joers; Marcia R Terluk; Abigail Travis; Kyle Rudser; Paul J Tuite; Neal J Weinreb; Jeanine R Jarnes; James C Cloyd; Gülin Öz Journal: J Inherit Metab Dis Date: 2019-12-17 Impact factor: 4.982
Authors: Amokelani C Mahungu; David G Anderson; Anastasia C Rossouw; Riaan van Coller; Jonathan A Carr; Owen A Ross; Soraya Bardien Journal: Neurobiol Aging Date: 2019-12-20 Impact factor: 4.673
Authors: Bouchra Ouled Amar Bencheikh; Etienne Leveille; Jennifer A Ruskey; Dan Spiegelman; Christopher Liong; Edward A Fon; Guy A Rouleau; Yves Dauvilliers; Nicolas Dupre; Roy N Alcalay; Ziv Gan-Or Journal: Neurobiol Aging Date: 2018-07-02 Impact factor: 4.673